Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of surovatamig (AZD0486) monotherapy in adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia
CTR20243136Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of surovatamig in B cell acute lymphoblastic leukemia (B-ALL), sponsored by AstraZeneca. Started Nov 2024; status: active.
02
Drugs
surovatamig
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20243136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243136.